These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Suramin. A new role for an old drug]. Soulie P; Cvitkovic E; Armand JP Rev Prat; 1994 May; 44(10):1358-61. PubMed ID: 7939197 [No Abstract] [Full Text] [Related]
4. Suramin: clinical uses and structure-activity relationships. McGeary RP; Bennett AJ; Tran QB; Cosgrove KL; Ross BP Mini Rev Med Chem; 2008 Nov; 8(13):1384-94. PubMed ID: 18991754 [TBL] [Abstract][Full Text] [Related]
5. [Suramin: pharmacology and antitumor effectiveness of an old parasiticide]. Rebollo J Med Clin (Barc); 1994 Mar; 102(8):301-5. PubMed ID: 8170229 [No Abstract] [Full Text] [Related]
8. Suramin selectively inhibits carcinoma cell growth that is dependent on extracellular polyamines. Sandgren S; Belting M Anticancer Res; 2003; 23(2B):1223-8. PubMed ID: 12820375 [TBL] [Abstract][Full Text] [Related]
9. Suramin: the discovery of an old anticancer drug. Zaniboni A Med Oncol Tumor Pharmacother; 1990; 7(4):287-90. PubMed ID: 2283894 [TBL] [Abstract][Full Text] [Related]
10. A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. Gradishar WJ; Soff G; Liu J; Cisneros A; French S; Rademaker A; Benson AB; Bouck N Oncology; 2000 May; 58(4):324-33. PubMed ID: 10838499 [TBL] [Abstract][Full Text] [Related]
11. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719 [TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Dawson NA; Cooper MR; Figg WD; Headlee DJ; Thibault A; Bergan RC; Steinberg SM; Sausville EA; Myers CE; Sartor O Cancer; 1995 Aug; 76(3):453-62. PubMed ID: 8625127 [TBL] [Abstract][Full Text] [Related]
13. Suramin as an archetypical compound in the development of growth factor antagonists for inhibition of genitourinary tumors. Scher HI; Heston WD Cancer Treat Res; 1992; 59():131-51. PubMed ID: 1347690 [No Abstract] [Full Text] [Related]
14. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Ahles TA; Herndon JE; Small EJ; Vogelzang NJ; Kornblith AB; Ratain MJ; Stadler W; Palchak D; Marshall ME; Wilding G; Petrylak D; Holland JC; Cancer; 2004 Nov; 101(10):2202-8. PubMed ID: 15484217 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins. Lawrence JB; Conover CA; Haddad TC; Ingle JN; Reid JM; Ames MM; Suman VJ; Marks RS; Erlichman C; Hartmann LC Clin Cancer Res; 1997 Oct; 3(10):1713-20. PubMed ID: 9815555 [TBL] [Abstract][Full Text] [Related]
18. Data modifications to phase I study of suramin. Kobayashi K; Vokes EE; Vogelzang NJ; Ratain MJ J Clin Oncol; 1996 Sep; 14(9):2623-4. PubMed ID: 8823343 [No Abstract] [Full Text] [Related]
19. Recent research on the biological activity of suramin. Voogd TE; Vansterkenburg EL; Wilting J; Janssen LH Pharmacol Rev; 1993 Jun; 45(2):177-203. PubMed ID: 8396782 [No Abstract] [Full Text] [Related]
20. Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate. Hemady RK; Sinibaldi VJ; Eisenberger MA Am J Ophthalmol; 1996 Mar; 121(3):291-6. PubMed ID: 8597272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]